Results 181 to 190 of about 495,708 (385)
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai +16 more
wiley +1 more source
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease [PDF]
Matthieu Allez +14 more
openalex +1 more source
Objective Spin refers to reporting strategies that highlight the benefits of an experimental treatment or divert attention from nonsignificant primary outcomes. To assess spin in randomized clinic trials (RCTs) on pharmaceutical efficacy in multiple sclerosis (MS) and explore associated factors.
Marta Mascareñas‐García +10 more
wiley +1 more source
Lactobacillus paragasseri SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial [PDF]
Eiji Kobatake +4 more
openalex +1 more source
We report the first human use of intranasal seletracetam (SEL) to prevent reflex seizures. A patient with epilepsy with reading‐induced seizures on levetiracetam (3,000 mg/day) continued to experience reading‐induced focal seizures with preserved consciousness.
Matthias J. Koepp +9 more
wiley +1 more source
Among patients with acute ischemic stroke achieving successful large vessel recanalization (defined as expanded Thrombolysis in Cerebral Infarction [eTICI ≥2b]), incomplete tissue‐level reperfusion, distinct from visually identifiable distal occlusion on digital‐subtraction angiography, remains a significant challenge.
Yue Qiao +4 more
wiley +1 more source
Effect of nano-curcumin supplementation on angina status, and traditional and novel cardiovascular risk factors in overweight or obese patients with coronary slow flow phenomenon: a randomized double-blind placebo-controlled clinical trial [PDF]
Mahsa Rezaei +7 more
openalex +1 more source

